



## **In reply to: Knowledge of developmental pharmacology and modeling approaches should be used to avoid useless trials in children**

Giovanni Tafuri, Francesco Trotta, Hubert G. M. Leufkens, Nello Martini, Luciano Sagliocca, Giuseppe Traversa

### **► To cite this version:**

Giovanni Tafuri, Francesco Trotta, Hubert G. M. Leufkens, Nello Martini, Luciano Sagliocca, et al.. In reply to: Knowledge of developmental pharmacology and modeling approaches should be used to avoid useless trials in children. *European Journal of Clinical Pharmacology*, 2009, 65 (8), pp.851-852. <10.1007/s00228-009-0677-9>. <hal-00534971>

**HAL Id: hal-00534971**

**<https://hal.science/hal-00534971v1>**

Submitted on 11 Nov 2010

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

## In reply to: Knowledge of developmental pharmacology and modeling approaches should be used to avoid useless trials in children

Giovanni Tafuri · Francesco Trotta ·  
Hubert G. M. Leufkens · Nello Martini ·  
Luciano Sagliocca · Giuseppe Traversa

Received: 27 May 2009 / Accepted: 29 May 2009 / Published online: 17 June 2009  
© The Author(s) 2009. This article is published with open access at Springerlink.com

We agree with de Wildt et al. on the need to take children's developmental changes into consideration when assessing the clinical evidence in order to waive additional studies.

In reviewing the available evidence on the use of proton pump inhibitors (PPIs) in the treatment of gastroesophageal reflux disease (GERD) in children, we focused on the age ranges for which no labeled indication was approved in the EU [1]. For example, in the case of omeprazole (authorized for the treatment of GERD in Europe for children  $\geq$  2 years), we searched for scientific literature based on children younger than 2 years. We found four trials entirely dedicated to children aged 0–2 years. The remaining two trials, although not strictly dedicated to that target population, also enrolled children between 0 and 2 years.

---

G. Tafuri · H. G. M. Leufkens  
Utrecht Institute for Pharmaceutical Sciences, Utrecht University,  
PO Box 80 082, 3508 TB Utrecht, The Netherlands

G. Tafuri · F. Trotta (✉) · G. Traversa  
Italian Medicines Agency (AIFA),  
via della Sierra Nevada 60,  
00144 Rome, Italy  
e-mail: f.trotta@aifa.gov.it

H. G. M. Leufkens  
Medicines Evaluation Board (MEB),  
PO Box 16229, 2500 BE The Hague, The Netherlands

N. Martini  
National Academy of Medicine,  
Via Martin Piaggio 17/6,  
16122 Genova, Italy

L. Sagliocca  
Local Health Unit Salerno 1,  
via Giovanni Falcone 70,  
84014 Nocera Inferiore (SA), Italy

Our review intended to deal with the general issue of off-label use of drugs in the pediatric population, to verify whether drugs not formally approved for use in a specific population may nonetheless present sufficient evidence supporting their (off-label) use. If the 0- to 2-year range is still considered too large to take into account the impact of developmental changes on a drug risk/benefit profile, further studies focusing on more specific age groups are clearly needed. Prior biological knowledge, or new data, are critical factors in deciding whether the available evidence is insufficient to guide clinical practice in a specific population sub-group.

However, we should also use a pragmatic and prioritizing approach, considering that requiring separate trials for each patient sub-group—in pediatrics as well as in other populations—may not be always feasible. For instance, in the case of the elderly, the combination of different age strata, co-morbidities, and concomitant use of different drugs may create an enormous number of potential different groups. The issue of how to generalize data deriving from a specific population to a wider population is inevitably to be considered on a case-by-case basis. Mathematical modeling may provide a contribution though, again, the applicability of existing evidence to different patient groups will continue to carry various degrees of uncertainty.

With regards to who should assess the use of off-label medicines in children, we agree on the importance of regulatory agencies in reviewing the available evidence to support clinical practice and to identify research priorities (a “to do” list). In the effort to deal with this issue, different strategies and approaches have been used at the regulatory level. In Europe, the EMEA Paediatric Committee has identified the needs in different therapeutic areas where there should be research and development of medicinal products for children [2]. In the U.S., the FDA has recently

released specific guidelines allowing drug manufacturers to distribute reprints of articles from medical journals that describe unapproved uses of their products, a practical attitude that can be of help in regulating evidence-based off-label drug use [3].

**Competing interests** The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the Italian Medicines Agency or the Medicines Evaluation Board.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which per-

mits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

## References

1. Tafuri G, Trotta F, Leufkens HG, Martini N, Sagliocca L, Traversa G (2009) Off-label use of medicines in children: can available evidence avoid useless paediatric trials? The case of proton pump inhibitors for the treatment of gastroesophageal reflux disease. *Eur J Clin Pharmacol* 65(2):209–216
2. EMEA (2007) Assessment of the paediatric needs—gastroenterology. EMEA/527934/2007. EMEA, London
3. Mello MM, Studdert DM, Brennan TA (2009) Shifting terrain in the regulation of off-label promotion of pharmaceuticals. *N Engl J Med* 360:1557–1566